New Concepts of Treatment for Patients with Myelofibrosis.

Abstract

OPINION STATEMENT:

Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. Patients who discontinue ruxolitinib have a dismal outcome, and this is, therefore, an area of significant unmet need. Given the central role that JAK-signal transducer and activator of transcription (STAT) activation plays in disease pathogenesis, there have been many other JAK inhibitors tested, but most have been abandoned, for a variety of reasons. The JAK2-selective inhibitor fedratinib has recently been resurrected, and there has been a resurgence of interest in the failed JAK1/2 inhibitor momelotinib, which possibly improves anemia. Pacritinib, a non-myelosuppressive JAK2-selective inhibitor, is currently in a dose-ranging study mandated by regulatory authorities. A plethora of other targeted agents, most backed by preclinical data, are in various stages of investigation. These include epigenetic and immune therapies, agents targeting cellular survival, metabolic and apoptotic pathways, the cell cycle, DNA repair, and protein folding and degradation, among others. However, at this time, none of these is close to registration or even in a pivotal trial, illustrating the difficulties in recapitulating the clinical disease in preclinical models. Most current clinical trials are testing the addition of a novel agent to ruxolitinib, either in the frontline setting or in the context of an insufficient response to ruxolitinib, or attempting to study new drugs in the second-line, "ruxolitinib failure" setting. Emerging data supports the addition of azacitidine to ruxolitinib in some patients. Other strategies have focused on improving cytopenias, through amelioration of bone marrow fibrosis or other mechanisms. This is important, because cytopenias are the commonest reason for ruxolitinib interruption and/or dose reduction, and dose optimization of ruxolitinib is tied to its survival benefit. The activin receptor ligand trap, sotatercept, and the anti-fibrotic agent, PRM-151, have shown promise in this regard.

• Authors: Prithviraj Bose, Mansour Alfayez, Srdan Verstovsek
• Journal: Current treatment options in oncology (Curr Treat Options Oncol) Vol. 20 Issue 1 Pg. 5 (01 24 2019) ISSN: 1534-6277 [Electronic] United States
• PMID: 30675650 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Nitriles
• Pyrazoles
• Pyrimidines
• ruxolitinib
• JAK1 protein, human
• JAK2 protein, human
• Janus Kinase 1
• Janus Kinase 2

Topics

• Clinical Trials as Topic
• Humans
• Janus Kinase 1 (antagonists & inhibitors, metabolism)
• Janus Kinase 2 (antagonists & inhibitors, metabolism)
• Nitriles
• Primary Myelofibrosis (drug therapy, enzymology, pathology)
• Prognosis
• Pyrazoles (therapeutic use)
• Pyrimidines